Hummingbird Bioscience Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 83

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 30

Hummingbird Bioscience General Information

Description

Developer of novel therapeutic antibody-based drugs designed to treat cancer and immuno-oncology patients. The company's drugs are developed based on a proprietary rational antibody discovery platform with deep experience in the application of integrative genomics and proteomics, enabling physicians to provide better treatments to cover the healthcare needs of patients that are not met by existing therapies.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • The Galen 61 Science Park Road
  • Number 06-15/24
  • Singapore, 117525
  • Singapore
+65 6266
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • The Galen 61 Science Park Road
  • Number 06-15/24
  • Singapore, 117525
  • Singapore
+65 6266

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hummingbird Bioscience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Secondary Transaction - Private Completed Clinical Trials - Phase 1
8. Later Stage VC (Series C) 15-Nov-2021 Completed Clinical Trials - Phase 1
7. Later Stage VC 06-Nov-2020 Completed Clinical Trials - Phase 1
6. Later Stage VC (Series B) 11-May-2020 Completed Clinical Trials - Phase 1
5. Early Stage VC (Series A) 01-Mar-2019 Completed Clinical Trials - Phase 1
4. Grant 25-Feb-2019 Completed Clinical Trials - Phase 1
3. Accelerator/Incubator 01-Jul-2018 Completed Startup
2. Early Stage VC 03-May-2017 Completed Startup
1. Accelerator/Incubator Completed Startup
To view Hummingbird Bioscience’s complete valuation and funding history, request access »

Hummingbird Bioscience Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B
Series A 11,548,952 $0.81 $0.81 1x $0.81 10.19%
To view Hummingbird Bioscience’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Hummingbird Bioscience Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel therapeutic antibody-based drugs designed to treat cancer and immuno-oncology patients. The company's
Drug Discovery
Singapore, Singapore
83 As of 2026

Watertown, MA
 

Madison, WI
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Hummingbird Bioscience Competitors (44)

One of Hummingbird Bioscience’s 44 competitors is Kymera Therapeutics, a Formerly VC-backed company based in Watertown, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kymera Therapeutics Formerly VC-backed Watertown, MA
Centrose Venture Capital-Backed Madison, WI
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
AUM Biosciences Venture Capital-Backed Singapore, Singapore
TME Pharma Formerly VC-backed Berlin, Germany
You’re viewing 5 of 44 competitors. Get the full list »

Hummingbird Bioscience Patents

Hummingbird Bioscience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026224308-A1 Methods of treating cancer Pending 24-Apr-2025
WO-2026221558-A1 Antibody-drug conjugates Pending 16-Apr-2025
WO-2026062200-A1 B7-h3 antigen-binding molecules Pending 20-Sep-2024
WO-2026063874-A1 B7-h3 antigen-binding molecules Pending 20-Sep-2024
WO-2026062072-A1 Vista antigen-binding molecules Pending 18-Sep-2024 C07K16/2827
To view Hummingbird Bioscience’s complete patent history, request access »

Hummingbird Bioscience Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Hummingbird Bioscience Investors (30)

Investor Name Investor Type Holding Investor Since Participating Rounds
5Y Capital Venture Capital Minority
Affinity Asset Advisors Hedge Fund Minority
Ally Bridge Group Growth/Expansion Minority
Altium Capital Management Growth/Expansion Minority
Amgen Ventures Corporate Venture Capital Minority
You’re viewing 5 of 30 investors. Get the full list »

Hummingbird Bioscience Investments (1)

Hummingbird Bioscience’s most recent deal was a Early Stage VC with Hillstar Bio for . The deal was made on 25-Mar-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Hillstar Bio 25-Mar-2025 Early Stage VC Drug Discovery
To view Hummingbird Bioscience’s complete investments history, request access »

Hummingbird Bioscience FAQs

  • When was Hummingbird Bioscience founded?

    Hummingbird Bioscience was founded in 2015.

  • Where is Hummingbird Bioscience headquartered?

    Hummingbird Bioscience is headquartered in Singapore, Singapore.

  • What is the size of Hummingbird Bioscience?

    Hummingbird Bioscience has 83 total employees.

  • What industry is Hummingbird Bioscience in?

    Hummingbird Bioscience’s primary industry is Drug Discovery.

  • Is Hummingbird Bioscience a private or public company?

    Hummingbird Bioscience is a Private company.

  • What is Hummingbird Bioscience’s current revenue?

    The current revenue for Hummingbird Bioscience is .

  • How much funding has Hummingbird Bioscience raised over time?

    Hummingbird Bioscience has raised $162M.

  • Who are Hummingbird Bioscience’s investors?

    5Y Capital, Affinity Asset Advisors, Ally Bridge Group, Altium Capital Management, and Amgen Ventures are 5 of 30 investors who have invested in Hummingbird Bioscience.

  • Who are Hummingbird Bioscience’s competitors?

    Kymera Therapeutics, Centrose, Adaptimmune Therapeutics, AUM Biosciences, and TME Pharma are some of the 44 competitors of Hummingbird Bioscience.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process